study question: Can sublingual administration of misoprostol 1 h prior to vacuum aspiration be more effective than vaginal administration and as effective as either route three 3 h prior to surgery?
.019) used for dilatation. The total priming time had a significant influence on bleeding before surgery, with more women bleeding the longer the total priming time (P ¼ 0.003, 95% CI 2.203, 49.706) . For abdominal pain before surgery there was a significant influence of administration route (P ¼ , 0.001 95% CI 0.028, 0.235) and the interaction variable between administration route and priming time (P ¼ 0.003, 95% CI 2.005, 30.757) with more women in the sublingual group experiencing abdominal pain the longer the priming time. The groups did not differ regarding duration of surgery, amount of bleeding and rate of side effects, such as nausea and shivering. Women in our study preferred vaginal treatment, as they disliked the taste of the misoprostol tablets. Vaginal treatment was also perceived as quicker to administer (P ¼ 0.0001).
limitations, reasons for caution: The cervical tissue has viscoelastic properties, i.e. tissue resistance to mechanical dilatation depends also on the rate at which dilatation is performed. The ideal measurement of dilatation force should therefore also record the rate and time of dilatation. To ensure comparability, only nulliparous women without prior cervical surgery were recruited. In addition, time of dilatation was recorded and did not differ between the groups, and it is therefore assumed that dilatation took place at approximately the same rate. A limitation is that the study was conducted over a long time period because there was only one tonometer, decreasing numbers of surgical abortions and the fact that the main author was on a rotation schedule. In addition, the study was not powered to detect differences in side effects.
wider implications of findings: Priming with misoprostol is recommended prior to surgical abortion. The priming interval of misoprostol may be reduced to 1 h after sublingual administration but not after vaginal administration. The results of the present study will increase choice and flexibility in cervical priming.
Introduction
In most countries where abortion is legal, vacuum aspiration is still the most common method used for first trimester abortion (WHO Medical methods for termination of pregnancy 1997; WHO Safe abortion: technical and policy guidance for health systems 2012). Misoprostol has been recommended prior to vacuum aspiration in women with an increased risk for complicated mechanical dilatation, such as young and nulliparous women, or women pregnant in the second trimester (Ngai et al., 1995; Fiala et al., 2007) . Recently it was shown that the administration of misoprostol can also reduce complications to surgical abortion in parous women (Meirik et al., 2012) . The recommended misoprostol dosage regimen for cervical priming is 400 mcg misoprostol administered vaginally 3 h prior to surgery (FIGO 2012) . A longer interval between administration and surgery did not result in a greater ripening effect but led to an increase in the rate of side effects . Sublingual misoprostol administration has also been studied. The absorption of misoprostol when given sublingually is as rapid as that observed following oral treatment, and peak plasma levels are reached significantly faster than following vaginal administration (Aronsson et al., 2007) . Vaginally administered misoprostol results in a slower uptake and fewer side effects compared with sublingual administration, but a longer lasting plasma concentration (Aronsson et al., 2007) . Studies have shown sublingual administration to be equally effective to vaginal administration after 2-3 h priming time (Hamoda et al., 2004; Tang et al., 2004) , but sublingual treatment results in significantly more side effects compared with vaginal treatment (Aronsson et al., 2004b; Hamoda et al., 2004) .
When misoprostol is used for priming prior to surgical abortion, heavy bleeding and expulsion may occur in some women before surgery is performed . The risk of bleeding and expulsion increases with the interval from administration of misoprostol to the procedure.
Reducing the priming interval would mean fewer side effects, less risk of aborting prior to surgery, less pain and greater flexibility concerning misoprostol administration. Side effects include abdominal pain, shivering, fever and bleeding prior to surgery. When misoprostol is selfadministered by women at home there is a risk of aborting before they reach the clinic. Based on the pharmacokinetics of the drug it is hypothesized that the sublingual route is superior to the vaginal route of administration of misoprostol, when the priming interval from drug administration to surgery is reduced to 1 h.
The primary objective was to compare, in a placebo controlled double-blind RCT, the baseline cervical dilatation after sublingual administration of misoprostol with the well-established vaginal administration of misoprostol, when administered at 1 h prior to surgical termination of pregnancy. Secondary objectives included a comparison of the efficacy of misoprostol administered by the sublingual or vaginal routes at a 1 or 3 h interval in baseline dilatation and cumulative force used for mechanical dilation, and to evaluate the side effects, blood loss and acceptability by the women undergoing treatment.
Materials and Methods
The trial was conducted in the department of Obstetrics and Gynecology at the Karolinska University hospital, Stockholm, Sweden, between June 2007 and March 2014.
The Regional Ethical Review Board at Karolinska Institutet approved the trial which was registered at Clincaltrials.gov, NCT01933360 and followed the CONSORT reporting guidelines for superiority trials. Prior to enrolment, a written informed consent was obtained from the patients. The trial was conducted according to the principles expressed in the Declaration of Helsinki.
Participants were recruited among nulliparous women requesting surgical termination of first trimester (gestational week 6 up to week 13) pregnancy.
In those who had been pregnant previously, all pregnancies had ended during the first trimester, either by termination of pregnancy or miscarriage. Participating women were of good general health, over 18 years of age, willing and able to participate and sign an informed consent. Exclusion criteria were any contraindication for misoprostol, untreated genital infection, previous history of surgery to the cervix, or abnormal pregnancy. The gestational age was established by endovaginal ultrasound examination. The patients were admitted to the hospital in the morning, having fasted overnight.
Women who met the inclusion criteria and who agreed to participate in the study, signed an informed consent either at the information visit prior to the abortion, or on the morning of the abortion in the clinic ward. Then they were randomly allocated to either treatment with sublingual misoprostol or vaginal misoprostol, as well as to either a 1 h or 3 h priming interval between misoprostol administration and surgery. The randomization was prepared using a computer generated randomization list. A research nursemidwife not directly involved in the study prepared numbered opaque and sealed envelopes containing the randomization number and women who consented to recruitment were randomized by consecutively opening the envelopes. A clinic nurse opened the envelopes, on the morning of the abortion when the patients were admitted to the ward. The study was placebo controlled.
Each envelope contained two tablets of 200 mcg misoprostol and two identical looking placebo tablets, with instructions for administration routes and priming time. Thus the dosage route was double blinded but not the priming interval. The randomization list was kept concealed from the investigators until the study was completed.
Patients administered the tablets themselves. All women received two tablets 200 mcg misoprostol (Cytotec w , Pfizer, Sweden) and two identically looking placebo tablets (Labatec-Pharma, Meyrin, Switzerland) 1 h or 3 h before surgery. The tablets were administered sublingually (SL) and vaginally (PV), thus the route of administration of misoprostol was concealed. Prophylactic pain medication, 100 mg oral diclofenac was administered at the time of misoprostol. Women were asked immediately before surgery if they had experienced abdominal pain, nausea or shivering after the administration of misoprostol. They were also asked which route of administration they found most convenient and which they would have preferred (vaginal or sublingual).
The exact priming time (from administration of misoprostol to initiation of mechanical dilatation) was recorded for each woman. In the groups with priming time of 1 h, it was considered as a violation of the study protocol if the priming time was shorter than 50 min or exceeded 90 min. In the groups with priming time of 3 h, it was considered as a violation of the study protocol and reason for exclusion if priming time was ,120 min and .3.5 h.
Signs of bleeding prior to dilatation were recorded. Cervical dilatation and vacuum aspiration were performed by one of two investigators (IS and KGD). The vacuum aspiration was performed under general anaesthesia according to clinical routine, which allows the patients to choose between local and general anaesthesia.
Dilatation was performed using tapered Pratt-dilatators and the resistance of the cervix was objectively assessed using a force-sensing handle (tonometer) attached to the dilator (Hulka et al., 1974) . The vacuum aspiration was performed according to clinical routine.
The primary outcome was the baseline dilatation of the cervix after medical priming with misoprostol. Baseline dilatation was considered as the largest dilatator that could enter the cervical os using a force of less than 8 Newton (N). If the smallest dilatator could not enter the cervical canal, the baseline was considered to be 4.1 mm (12 French), which was reported to be the mean dilatation in nulliparous women before priming with misoprostol (Ngai et al., 1995) . The cervical canal was dilated with dilators from 6.3 mm (19 French) up to 9.7 mm (29 French), or in some cases with pregnancies over 11 weeks up to 11 mm (33 French). The cumulative force required to dilate the cervix was calculated by adding the peak force needed for each dilatator up to 9.7 mm.
The time needed for surgery, including cervical dilatation and vacuum aspiration, was recorded using a stopwatch. Also, the time needed for dilatation was recorded by recording the time used for each dilator to enter the internal os, and then adding the results for all dilators. The intra-operative blood loss was measured as the volume of uterine aspirate after sieving away the products of conception. Any surgical complications were noted. Before and after the surgery, blood pressure, pulse and temperature were recorded.
Statistics
Sample size calculation A previous study showed the baseline cervical os to be 4.1 mm with SD 1.4 in untreated nulliparous women (Ngai et al., 1995) , and that 400 mcg of misoprostol resulted in cervical baseline dilatation [mean (SD)] 3 h after treatment of 7.7 mm (0.73) following vaginal administration, and 7.6 mm (1.3) following sublingual treatment (Tang et al., 2004) . A difference of 1 mm in baseline dilatation has been considered clinically relevant in previous studies (Ngai et al., 1996) , and should correspond to a difference in force needed for mechanical dilatation. Therefore, a sample size of 42 women in each arm would provide 80% power to detect a minimum difference of that magnitude in baseline dilatation, when testing for superiority with a two-sided 5% Students's t-test. Assuming a 10% loss of data, the number estimated to be recruited was 46 women per group. Thus the total sample size was determined to be 184 women.
For testing if the group of SL treatment for 1 h is non-inferior to 3 h, a noninferiority test was performed. In a non-inferiority test, the null hypothesis is that the suggested method (SL 1 h) performs worse than the known method (SL 3 h), and the alternative hypothesis to be proven is that the suggested method (SL 1 h) is 'equally good or better' than the known method (SL 3 h). The non-inferiority test was assessed through a two-sided 95% confidence interval (CI). A difference of ,0.5 mm in baseline dilatation was considered clinically irrelevant (Hamoda et al., 2004) . The non-inferiority test was also performed for peak force and cumulative force, where a difference of less than 5N and 10N, respectively, was considered clinically irrelevant.
Differences between normally distributed parameters were analysed using the Student's t-test. Differences between non-normally distributed parameters were analysed using the Mann-Whitney U-test. Categorical variables were analysed using Fisher's exact test. Results were regarded as statistically significant if P-values were ,0.05.
In addition we performed a multivariate linear regression analysis with backwards elimination for the outcomes baseline dilatation, peak force, and cumulative force. For the outcomes abdominal pain and bleeding we performed a logistic regression analysis with backwards elimination. The factors analysed were priming time (min), route of administration (SL/PV), Gestational length (days), BMI and previous spontaneous abortion. We created an interaction variable for priming time with actual priming time in minutes and route of administration (SL/PV). In addition we also had a dichotomized treatment variable for treatment time (1 or 3 h) for use in a logistic regression model for dichotomous outcomes. The interaction variable was changed according to this.
All statistical calculations were performed using IBS Statistical Package for Social Sciences (SPSS, IBM Corporation, Armonk, NY, USA).
Results
During the study period 2711 surgical abortions were performed in the clinic, of which 1399 were in nulliparous women (Fig. 1) . Among the 200 nulliparous women who did not meet the inclusion criteria 140 were under the age of 18 years, and 92 patients declined to participate. Surgical abortion was performed 2 days per week and as the surgical dilatation was performed with special force measuring tonometer equipment, it was only possible to enrol a maximum of two women per operation day. Two of the investigators performed all the surgical abortions in the study patients (I.S. and K.G.-D.). Patients were only enrolled in the study when one of the two study investigators was available to perform the abortion. Due to these logistical reasons, 923 eligible women were not invited to participate. A total of 184 women were included in the study. Six women were retrospectively excluded. Two of them had been included by mistake in spite of previous childbirth, and four were excluded due to priming time outside defined limits.
The duration of pregnancy was between 42 and 85 days (6 and 13 weeks) at the time of surgery, with mean gestational length varying from 63 to 66 days in the different groups (Table I ). There were no differences between the groups in demographic characteristics such as age, BMI and gestational length ( Table I ). The exact priming time (administration of misoprostol to initiation of mechanical dilatation) was recorded for each woman and mean priming time was 64.5 (range 56 -77) minutes for the sublingual 1-h group, 64.1 (range 54 -78) minutes in the vaginal 1-h group, 180 (range 120-210) minutes in the sublingual 3-h group and 185 (range 127-187) minutes in the vaginal 3-h group. 
Misoprostol for cervical priming
The time for dilatation, duration of surgery and amount of bleeding for each group is presented in Table II There was a clear correlation between the baseline dilatation and cumulative force needed for dilatation (Fig. 2) . Mean baseline dilatation, peak force and cumulative force for the different groups are presented in Table III . In the final model for the linear regression analysis of the baseline dilatation, the route of administration showed a significant correlation to the priming effect measured as the primary outcome baseline dilatation (P ¼ 0.034, 95% CI 22.202, 20.086). Also, the interaction between the route of administration and the priming time in minutes showed a significant correlation due to the fact that the priming effect of the vaginal route is improved with longer priming time (P ¼ 0.042 95% CI (0.00, 0.016). There was also a significant influence of the gestational length, with a progression in gestational length being positively correlated to a greater baseline dilation (P , 0.001, 95% CI 0.022, 0.063). Corresponding to baseline dilatation, similar significant correlations apply to the related outcomes peak force (P ¼ 0.049, 95% CI 20.089, 0.000) and cumulative force (P ¼ 0.026, 95% CI 20.293, 20.019). All results of the final linear regression models are presented in Table IV . Sublingual 1 h priming was proven to be equal or better (non-inferior) compared with sublingual 3 h priming for baseline dilatation (CI 20.42, 0.95), peak force (CI 24.1, 2.9) and cumulative force (CI 214.4, 9.5) analysed in a univariate analysis.
There were no serious adverse events, such as cervical tearing, uterine perforation or severe haemorrhage over 500 ml, in the study. percentages of women experiencing side effects are presented in Table V . The final logistic regression model for the outcome bleeding before surgery shows that the priming time significantly influences the likelihood of bleeding before surgery (P ¼ 0.003, 95% CI 2.203, 49.706). Higher gestational length is also positively correlated to experiencing bleeding before surgery (P ¼ 0.046, 95% CI 0.917, 0.999). The final model for the logistic regression analysis of the outcome abdominal pain before surgery shows that the sublingual administration is associated with a higher incidence of abdominal pain before surgery compared with vaginal administration (P , 0.001). However, the significant influence of the interaction variable between route of administration and priming time shows that the results are influenced by the total priming time before surgery. Longer priming time using the sublingual route of administration is significantly correlated to experiencing abdominal pain before surgery (P ¼ 0.003, 95% CI 2.005, 30.757). All results of the final logistic regression models are presented in Table VI . Acceptability was high in all groups but 134 (75%), of the women stated that they preferred the vaginal route of administration (P ¼ 0.0001), 28 (16%) preferred sublingual treatment and 16 (9%) found the routes of administration equally acceptable. Reasons for preferring the vaginal route of administration were that women found it easy and quick to administer, while negative features of sublingual administration were taste and the long time it took for the tablets to dissolve. Women, irrespective of if they preferred sublingual and vaginal treatment, found their preference to be the most convenient and easy route of administration. The results concerning preference did not differ when analysed by group (active versus placebo).
Discussion
Sublingual administration of 400 mcg of misoprostol 1 h prior to vacuum aspiration was shown to be significantly more effective compared with the vaginal route and as effective as priming by either route 3 h prior to surgery, both in reaching a baseline dilatation and in cumulative force needed for mechanical dilatation. Sublingual priming for 1 h was proven non-inferior to 3 h sublingual priming, in regard to baseline dilatation, peak force and cumulative force. There was a clear correlation between the baseline dilatation and the cumulative force needed for dilatation. Baseline cervical dilatation following 1 h sublingual misoprostol priming was also equal to baseline dilatation after 3 h priming interval which in turn corresponded well with that observed in previous studies (Ngai et al., 1995; Aronsson et al., 2004a,b; Hamoda et al., 2004; Tang et al., 2004) . In contrast shortening the priming interval for vaginally administered misoprostol to 1 h resulted in reduced efficacy.
As previously shown, gestational length is an important factor for baseline dilatation (MacIsaac et al., 1999) . This was also the result in our study. Since women with short gestational length will have a smaller baseline dilatation, they are likely to benefit as much from cervical priming even if they do not need to be dilated to the largest size dilator. This is also in accordance with the result of a large multicentre study (Meirik et al., 2012) .
While waiting 3 h did not improve the efficacy of the sublingually administered misoprostol, it resulted in significantly more women who had started bleeding. This knowledge is of great importance, since women are often admitted in the morning shortly before surgery and asked to administer misoprostol at home to reach a priming interval of 3 h. This means an obvious risk of bleeding, and possibly expulsion, before reaching the clinic. When priming interval is reduced to 1 h, misoprostol can be administered shortly before surgery while admitting the patient, eliminating the risk of expulsion before reaching the clinic.
Vaginal treatment has in previous studies been shown to induce less side effects, particularly gastrointestinal side effects and shivering, compared with misoprostol administered sublingually or orally (Aronsson et al., 2004a,b) . Sublingual administration results in high peak plasma levels of the active misoprostol free acid, which may lead to more side effects (Tang et al., 2004) . Sublingual administration also results in a pronounced effect on uterine tonus, which is consistent with the reported cramping and lower abdominal pain. This effect is less pronounced for vaginally administered misoprostol (Aronsson et al., 2004a,b) . It is a weakness of the study that it is underpowered to detect differences in common side effects. Interestingly and in contrast to some prior studies, a majority of the women in our study preferred the vaginal route (Ho et al., 1997; Ngai et al., 2000) . Reasons reported for this were mainly the taste and the slow dissolving of the tablets when taken sublingually. One important difference compared with previous studies is that women in our study were allowed to administer the vaginal tablets themselves which may have increased acceptability of the vaginal route.
Previous studies have frequently used Hegar type dilators: However, dilatation of the cervix using the tapered Pratt dilatators has been shown to require less force than the cone shaped Hegar dilatators (Hulka et al., 1974) . As little force as possible should be used when dilating the cervix in order to cause as little damage as possible, and to reduce the risk of perforation. The cervical tissue has viscoelastic properties, meaning the tissue resistance to mechanical dilatation depends also on the rate of which dilatation are performed. The ideal measurement of dilatation force should therefore also record the rate and time of dilatation. To ensure comparability, the time of dilatation was recorded, and did not differ between the groups, and it is therefore assumed that dilatation took place at approximately the same rate.
A limitation of the study is that it was conducted over a long period of time (7 years) due to the fact that there was only one tonometer, a decreasing number of surgical abortions in the clinic and the fact that the main author was on a rotation schedule. It is a strength however; that all surgery was performed by only two highly experienced investigators well acquainted with the tonometer equipment. Another limitation is that the study was not powered for subgroup analyses, or for detection of differences concerning side effects.
The major strength of the study is the stringent study protocol based on a randomized placebo controlled double-blind design. We included only nulliparous women, to ensure comparability of the baseline cervical dilatation (Oppegaard et al, 2004) . However, also parous women have been proven to benefit from priming treatment with misoprostol prior to surgical abortion, as this reduces the overall risk of complications during dilatation and vacuum aspiration and the risk for incomplete abortion (Meirik et al., 2012) .
Conclusions
Sublingual treatment with 400 mcg misoprostol for cervical dilatation 1 h prior to vacuum aspiration is significantly more effective than vaginal treatment. Furthermore, a 1 h priming interval is as effective as a 3 h priming interval with either route of misoprostol. Significantly fewer women start bleeding prior to surgery following the shorter, 1 h priming interval. Thus, the priming interval may be reduced to 1 h when misoprostol is administered sublingually. If misoprostol is administered vaginally, a 3 h priming interval is needed for equal efficacy. The results of the present study will increase choice and flexibility in cervical priming prior to surgical interventions. 
